arrow
L

Lisa C. Lindesmith

university of north carolina - chapel hill
H指数:39
被引数:9,015

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Norovirus GII.4 serological repertoire in older adults after GII.4 ancestral variant vaccination: a post-hoc analysis of a randomised, double-blind, phase 2 trial

诺如病毒GII.4血清学谱在GII.4祖先变异株疫苗接种后的老年人中:一项随机、双盲、二期试验的事后分析

2026-05-150
OAAI
One-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine development

单组分可离子化两亲性Janus树状大分子作为高效mRNA疫苗开发的递送平台

2026-03-270
OA
Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus

广谱中和抗体靶向大流行性GII.4变种或人诺如病毒的七种GII基因型

2025-03-050
PRE
Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection
2024-10-011
OAAI
Emergence of Novel Norovirus GII.4 Variant

新型诺如病毒GII.4变体的出现

2024-01-017
OAAI
Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters
2023-08-182
OAAI
Progress in vaccine development for infectious diseases-a Keystone Symposia report

传染病疫苗开发的进展-Keystone专题讨论会报告

2023-04-054
PRE
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later
2023-03-0112
OAAI
Immune Imprinting Drives Human Norovirus Potential for Global Spread
MBIO
IF4.7
2022-10-2623
OAAI
Efficacy of pediatric SARS-CoV-2 vaccines against high-dose B.1.617.2 challenge one year after vaccination of infant rhesus macaques
2022-05-010
PRE
Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum
2022-02-086
OA